{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 0,
        "end": 10
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 43,
        "end": 46
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 74,
        "end": 79
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 110,
        "end": 113
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 51,
        "end": 54
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 118,
        "end": 121
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 51,
        "end": 64
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22989574_5",
  "text": "Crizotinib continued to be developed as an ALK and MET inhibitor in other tumor types driven by alteration in ALK and MET ."
}
